Safety and efficacy of anisodamine on prevention of contrast induced nephropathy in patients with acute coronary syndrome

Chinese Medical Journal

Volumn 125, Issue 6, 2012, Pages 1063-1067

  Wang, Yan Bo ^a   Fu, Xiang Hua ^a   Gu, Xin Shun ^a   Wang, Xue Chao ^a   Zhao, Yu Jun ^a   Hao, Guo Zhen ^a   Jiang, Yun Fa ^a   Fan, Wei Ze ^a   Wu, Wei Li ^a   Li, Shi Qiang ^a   Xue, Ling ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Anisodamine; Contrast induced nephropathy; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANISODAMINE; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IOHEXOL; PLACEBO; VASODILATOR AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BLURRED VISION; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PALPITATION; HEART RATE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; THIRST; URINE RETENTION;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY, BALLOON, CORONARY; CONTRAST MEDIA; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; SOLANACEOUS ALKALOIDS;

EID: 84863539093     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Weisbord SD, Chen H, Stone RA, Kip KE, Fine MJ, Saul MI, et al. Association of increase in serum creatinine with mortality and length of hospital stay after coronary angiography. J Am Soc Nephrol 2006; 17: 2871-2877.
2. Shoukat S, Gowani SA, Jafferani A, Dhakam SH. Contrast-induced nephropathy in patients undergoing percutaneous coronary intervention. Cardiol Res Pract 2010; 2010: 1-12.
3. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. Kidney Int 2005; 68: 14-22.
4. Palevsky PM. Defining contrast-induced nephropathy. Clin J Am Soc Nephrol 2009; 4: 1151-1153.
5. Mautone A, Brown JR. Contrast-induced nephropathy in patients undergoing elective and urgent procedures. J Interv Cardiol 2010; 23: 78-85.
6. Xiu RJ, Hammerschmidt DE, Coppo PA, Jacob HS. Anisodamine inhibits thromboxane synthesis, granulocyte aggregation, and platelet aggregation. A possible mechanism for its efficacy in bacteremic shock. JAMA 1982; 247: 1458-1460.
7. Poupko JM, Baskin SI, Moore E. The pharmacological properties of anisodamine. J Appl Toxicol 2007; 27: 116-121.
8. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
9. Zhang J, Fu X, Jia X, Fan X, Gu X, Li S, et al. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Acta Radiologica 2010; 51: 641-648.
10. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104: 519-524.
11. Brar SS, Shen AY, Jorgensen MB, Kotlewski A, Aharonian VJ, Desai N, et al. Sodium bicarbonate vs. sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 2008; 300: 1038-1046.
12. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2005; 165: 1087-1093.
13. Marenzi G, Lauri G, Campodonico J, Marana I, Assanelli E, De Metrio M, et al. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. Am J Med 2006; 119: 155-162.
14. Heinrich MC, Häberle L, Müller V, Bautz W, Uder M. Nephrotoxity of iso-osmolar iodixanol compared with momionic low-osmolar contrast media: meta-analysis of randomized controlled trials. Radiology 2009; 25: 68-86.
15. Zoungas S, Ninomiya T, Huxley R, Cass A, Jardine M, Gallagher M, et al. Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. Ann Intern Med 2009; 151: 631-638.
16. Fu XH, Fan WZ, Gu XS, Wei YY, Jiang YF, Wu WL, et al. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction. Chin Med J 2007; 120: 1226-1231.
17. Zou AP, Parekh N, Steinhausen M. Effect of anisodamine on the microcirculation of the hydronephrotic kidney of rats. Int J Microcirc Clin Exp 1990; 9: 285-296.
18. Liu X, Zhang J. An experimental study on the mechanism of anisodamini hydrobromidum in treating acute ischemic renal failure. J Tongji Med Univ 1998; 18: 187-189.
19. 2+ transients in isolated adult rat ventricular myocytes. Eur J Pharmacol 2002; 439: 21-25.
20. Nakagawa S, Kushiya K, Taneike I, Imanishi K, Uchiyama T, Yamamoto T. Specific inhibitory action of anisodamine against a staphylococcal superantigenic toxin, toxic shock syndrome toxin 1 (TSST-1), leading to down-regulation of cytokine production and blocking of TSST-1 toxicity in mice. Clin Diagn Lab Immunol 2005; 12: 399-408.